Cargando…

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias

T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Braunstein, Zachary, McLaughlin, Eric, Ruiz, Miguel, Wei, Lai, Bumma, Naresh, Benson, Don, Devarakonda, Srinivas, Chaudhry, Maria, Khan, Abdullah, Cottini, Francesca, Hanel, Walter, Baiocchi, Robert, Chung, Catherine, Addison, Daniel, Couette, Nina, Meara, Alexa, Jarjour, Wael, Porcu, Pierluigi, Mishra, Anjali, Reneau, John C., Rosko, Ashley E., Brammer, Jonathan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106372/
https://www.ncbi.nlm.nih.gov/pubmed/35574379
http://dx.doi.org/10.3389/fonc.2022.858426
_version_ 1784708268205015040
author Braunstein, Zachary
McLaughlin, Eric
Ruiz, Miguel
Wei, Lai
Bumma, Naresh
Benson, Don
Devarakonda, Srinivas
Chaudhry, Maria
Khan, Abdullah
Cottini, Francesca
Hanel, Walter
Baiocchi, Robert
Chung, Catherine
Addison, Daniel
Couette, Nina
Meara, Alexa
Jarjour, Wael
Porcu, Pierluigi
Mishra, Anjali
Reneau, John C.
Rosko, Ashley E.
Brammer, Jonathan E.
author_facet Braunstein, Zachary
McLaughlin, Eric
Ruiz, Miguel
Wei, Lai
Bumma, Naresh
Benson, Don
Devarakonda, Srinivas
Chaudhry, Maria
Khan, Abdullah
Cottini, Francesca
Hanel, Walter
Baiocchi, Robert
Chung, Catherine
Addison, Daniel
Couette, Nina
Meara, Alexa
Jarjour, Wael
Porcu, Pierluigi
Mishra, Anjali
Reneau, John C.
Rosko, Ashley E.
Brammer, Jonathan E.
author_sort Braunstein, Zachary
collection PubMed
description T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. There was no survival difference in patients with CTCL or T-LGLL and concomitant PCD when treated with standard therapy directed at the T-cell malignancy when compared to historical controls. However, patients with PTCL and concomitant PCD had significantly inferior outcomes with rapid progression and worse OS and PFS at 1.7 years (p=0.006) and 4.8 months (p=0.08), respectively, when compared to historical controls for patients with PTCL, although the limited number of patients included in this analysis precludes drawing definitive conclusions. Treatment directed at the T-cell malignancy resulted in the eradication of the PCD clone in multiple patients (15.4%) including one with multiple myeloma (MM) who experienced a complete response after starting therapy directed at the T-cell malignancy. For patients with T-cell malignancies and concomitant PCD, treatment with standard T-cell-directed therapies is recommended based on this analysis with continued follow-up and monitoring of the concomitant PCD. Further studies are needed to definitively elucidate the increased risk of relapse in patients with PTCL and concomitant PCD, and larger, multi-center cohorts are needed to validate these findings across T-cell malignancies and PCDs.
format Online
Article
Text
id pubmed-9106372
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91063722022-05-14 Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias Braunstein, Zachary McLaughlin, Eric Ruiz, Miguel Wei, Lai Bumma, Naresh Benson, Don Devarakonda, Srinivas Chaudhry, Maria Khan, Abdullah Cottini, Francesca Hanel, Walter Baiocchi, Robert Chung, Catherine Addison, Daniel Couette, Nina Meara, Alexa Jarjour, Wael Porcu, Pierluigi Mishra, Anjali Reneau, John C. Rosko, Ashley E. Brammer, Jonathan E. Front Oncol Oncology T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. There was no survival difference in patients with CTCL or T-LGLL and concomitant PCD when treated with standard therapy directed at the T-cell malignancy when compared to historical controls. However, patients with PTCL and concomitant PCD had significantly inferior outcomes with rapid progression and worse OS and PFS at 1.7 years (p=0.006) and 4.8 months (p=0.08), respectively, when compared to historical controls for patients with PTCL, although the limited number of patients included in this analysis precludes drawing definitive conclusions. Treatment directed at the T-cell malignancy resulted in the eradication of the PCD clone in multiple patients (15.4%) including one with multiple myeloma (MM) who experienced a complete response after starting therapy directed at the T-cell malignancy. For patients with T-cell malignancies and concomitant PCD, treatment with standard T-cell-directed therapies is recommended based on this analysis with continued follow-up and monitoring of the concomitant PCD. Further studies are needed to definitively elucidate the increased risk of relapse in patients with PTCL and concomitant PCD, and larger, multi-center cohorts are needed to validate these findings across T-cell malignancies and PCDs. Frontiers Media S.A. 2022-04-29 /pmc/articles/PMC9106372/ /pubmed/35574379 http://dx.doi.org/10.3389/fonc.2022.858426 Text en Copyright © 2022 Braunstein, McLaughlin, Ruiz, Wei, Bumma, Benson, Devarakonda, Chaudhry, Khan, Cottini, Hanel, Baiocchi, Chung, Addison, Couette, Meara, Jarjour, Porcu, Mishra, Reneau, Rosko and Brammer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Braunstein, Zachary
McLaughlin, Eric
Ruiz, Miguel
Wei, Lai
Bumma, Naresh
Benson, Don
Devarakonda, Srinivas
Chaudhry, Maria
Khan, Abdullah
Cottini, Francesca
Hanel, Walter
Baiocchi, Robert
Chung, Catherine
Addison, Daniel
Couette, Nina
Meara, Alexa
Jarjour, Wael
Porcu, Pierluigi
Mishra, Anjali
Reneau, John C.
Rosko, Ashley E.
Brammer, Jonathan E.
Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
title Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
title_full Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
title_fullStr Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
title_full_unstemmed Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
title_short Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
title_sort incidence, treatment, and survival of patients with t-cell lymphoma, t-cell large granular leukemia, and concomitant plasma cell dyscrasias
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106372/
https://www.ncbi.nlm.nih.gov/pubmed/35574379
http://dx.doi.org/10.3389/fonc.2022.858426
work_keys_str_mv AT braunsteinzachary incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT mclaughlineric incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT ruizmiguel incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT weilai incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT bummanaresh incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT bensondon incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT devarakondasrinivas incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT chaudhrymaria incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT khanabdullah incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT cottinifrancesca incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT hanelwalter incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT baiocchirobert incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT chungcatherine incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT addisondaniel incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT couettenina incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT mearaalexa incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT jarjourwael incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT porcupierluigi incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT mishraanjali incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT reneaujohnc incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT roskoashleye incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias
AT brammerjonathane incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias